Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B-cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma (Multicenter, Open-label).

NCT01718691 is registered in ClinicalTrials.gov with SymBio Pharmaceuticals as lead sponsor.

NCT NCT01718691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01718691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B-cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma (Multicenter, Open-label).
Lead sponsor
SymBio Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
November 30, 2013
Enrollment
70 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

low-grade b cell non-hodgkin's lymphoma, mantle cell lymphoma where hematopoietic stem cell transplantation is not indicated